Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. [electronic resource]
Producer: 20070522Description: 561-74 p. digitalISSN:- 0344-5704
- Actins -- metabolism
- Adenocarcinoma, Clear Cell -- blood supply
- Angiogenesis Inhibitors -- therapeutic use
- Animals
- Antineoplastic Agents -- therapeutic use
- Benzenesulfonates -- therapeutic use
- Capillaries -- pathology
- Cell Line, Tumor
- Female
- Humans
- Hypoxia -- chemically induced
- Immunohistochemistry
- In Situ Nick-End Labeling
- Kidney Neoplasms -- blood supply
- Mice
- Mice, Nude
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Platelet Endothelial Cell Adhesion Molecule-1 -- immunology
- Pyridines -- therapeutic use
- Regional Blood Flow -- drug effects
- Sorafenib
- Vascular Endothelial Growth Factor A -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.